维奈克拉联合阿扎胞苷治疗复发或难治性T细胞急性淋巴细胞白血病:多中心单臂2期试验
这项多中心单臂2期试验纳入25例15-70岁复发或难治性T细胞急性淋巴细胞白血病患者,给予维奈克拉联合阿扎胞苷方案,总缓解率为76%(19/25),完全缓解率36%(9/25);常见≥3级血液学不良事件为中性粒细胞减少84%(21/25)、贫血44%(11/25)等,未观察到治疗相关严重不良事件或治疗相关死亡。
要点
- 维奈克拉联合阿扎胞苷方案总缓解率为76%(19/25),完全缓解率36%(9/25)。
- 最常见≥3级血液学不良事件为中性粒细胞减少84%(21/25)、贫血44%(11/25)。
- 未观察到治疗相关严重不良事件或治疗相关死亡。
核心结论
- 维奈克拉联合阿扎胞苷方案作为复发或难治性T细胞急性淋巴细胞白血病的挽救治疗,安全性可控且显示出有前景的活性。
- 鉴于样本量有限和单臂设计,需要进一步确证性试验来验证其作为潜在挽救治疗的疗效。
研究设计与样本
- 多中心、单臂、2期试验,纳入25例15-70岁复发或难治性T细胞急性淋巴细胞白血病且ECOG体能状态评分为0-3的患者。
- 维奈克拉联合阿扎胞苷方案:维奈克拉第1天100 mg、第2天200 mg、第3-21天400 mg口服;阿扎胞苷第1-7天每日75 mg/m2皮下注射。
- 主要终点为总缓解率,在包含所有入组患者的全分析集中进行活性分析;试验注册号为NCT05149378,已完成。
- 入组时间为2021年11月28日至2024年12月31日;数据截止日期为2025年4月7日。
主要发现
- 入组25例患者,中位年龄39.0岁(IQR 27.5-56.5);男性18例(72%),女性7例(28%);所有患者均为亚洲人。
- 总缓解率为76%(19/25),其中完全缓解36%(9/25)、完全缓解伴部分血液学恢复16%(4/25)、完全缓解伴不完全血液学恢复16%(4/25)、形态学无白血病状态8%(2/25)。
- 截至数据截止日期2025年4月7日,中位随访时间为31.8个月(IQR 16.2-39.3)。
- 最常见≥3级血液学不良事件为中性粒细胞减少84%(21/25)、贫血44%(11/25)、发热性中性粒细胞减少40%(10/25)、血小板减少20%(5/25),其次为感染12%(3/25)。
- 未观察到治疗相关严重不良事件,未发生治疗相关死亡。
关键数值与推荐
- 完全缓解率为36%(9/25)。
- 中位随访时间为31.8个月(IQR 16.2-39.3)。
临床怎么用
- 作者认为,维奈克拉联合阿扎胞苷方案作为复发或难治性T细胞急性淋巴细胞白血病的挽救治疗,安全性可控且显示出有前景的活性。
- 作者指出,鉴于样本量有限和单臂设计,需要进一步确证性试验来验证其作为潜在挽救治疗的疗效。
局限性
- 样本量有限。
- 单臂设计。
- 需要进一步确证性试验来验证其作为潜在挽救治疗的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with relapsed or refractory T-cell acute lymphoblastic leukaemia have limited responses to conventional chemotherapy and poor prognoses. T-cell precursors exhibit high expression of BCL-2 and are sensitive to BCL-2 inhibitors. Retrospective case series have reported the successful use of venetoclax combined with chemotherapy or hypomethylating agents when treating relapsed or refractory T-cell acute lymphoblastic leukaemia. The study aimed to evaluate the activity and safety of the venetoclax plus azacitidine regimen in patients with relapsed or refractory T-cell acute lymphoblastic leukaemia. METHODS: In this single-arm, phase 2, multicentre trial, patients aged 15-70 years with relapsed or refractory T-cell acute lymphoblastic leukaemia and an Eastern Cooperative Oncology Group performance status of 0-3 were eligible. The venetoclax plus azacitidine regimen consisted of venetoclax (100 mg on day 1, 200 mg on day 2, and 400 mg on days 3-21, orally) and azacitidine (75 mg/m2 per day on days 1-7, subcutaneously). The primary endpoint was overall response rate. Activity analyses were performed in the full analysis set that included all enrolled patients. This trial is registered with ClinicalTrials.gov (NCT05149378) and is complete. FINDINGS: Between Nov 28, 2021, and Dec 31, 2024, 25 patients were enrolled. The median age at enrolment was 39·0 years (IQR 27·5-56·5); 18 patients (72%) were male and seven (28%) were female; and all patients were Asian. The overall response rate was 76% (19 of 25; 36% [nine of 25] for complete remission, 16% [four of 25] for complete remission with partial haematological recovery, 16% [four of 25] for complete remission with incomplete haematological recovery, and 8% [two of 25] for morphological leukaemia-free state). As of the data cutoff (April 7, 2025), median follow-up was 31·8 months (IQR 16·2-39·3). The most common grade 3 or worse haematological adverse events were neutropenia (21 [84%] of 25), anaemia (11 [44%] of 25), febrile neutropenia (ten [40%] of 25), and thrombocytopenia (five [20%] of 25), followed by infections (three [12%] of 25). No treatment-related serious adverse events were observed and no treatment-related deaths occurred. INTERPRETATION: The venetoclax plus azacitidine regimen showed a manageable safety profile and promising activity as salvage therapy for relapsed or refractory T-cell acute lymphoblastic leukaemia. Given the limited sample size and single-arm design nature, further confirmatory trials are warranted to validate its efficacy as a potential salvage therapy for relapsed or refractory T-cell acute lymphoblastic leukaemia. FUNDING: National Natural Science Foundation of China. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
引用
- Cao HY, Zhang H, Zhang Y, et al. Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2025. PMID: 41338863. doi:10.1016/S2352-3026(25)00284-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。